4.6 Review

AUGMENTATION STRATEGIES FOR TREATMENT-RESISTANT ANXIETY DISORDERS: A SYSTEMATIC REVIEW AND META-ANALYSIS

期刊

DEPRESSION AND ANXIETY
卷 33, 期 8, 页码 728-736

出版社

WILEY
DOI: 10.1002/da.22525

关键词

treatment resistance; anxiety/anxiety disorders; clinical trials; pharmacotherapy; antidepressants; GAD/generalized anxiety disorder; SAD/social anxiety disorder/social phobia; panic attacks/agoraphobia

资金

  1. National Institute of Mental Health

向作者/读者索取更多资源

Background: A systematic review and meta-analysis was conducted to explore the efficacy of medication augmentation strategies compared to control treatments in patients who have had a partial or no response to initial treatment for generalized anxiety disorder, social anxiety disorder, and panic disorder. Methods: Double-blind controlled trials of medication augmentation in adult treatment-resistant anxiety disorders conducted between January 1990 and January 2015 were systematically reviewed and evaluated by two independent raters. The search identified 625 articles; 610 were excluded following abstract review and 15 had full-text screening. Studies had to include a definition of treatment resistance, exclude concomitant medications, and have a parallel or crossover design. Data extraction forms were completed in duplicate. Results: Six studies were included in the meta-analysis. Effect estimates were calculated using random effects modeling; heterogeneity was assessed and subgroup and sensitivity analyses were completed. Primary outcome was response, defined by Clinical Global Impression-Improvement score of <= 2. Augmentation was not associated with an increased risk of response, as compared with placebo (RR = 1.08, 95% CI = 0.94-1.24). A small significant effect was found in reduction in symptom severity: standard mean difference = -0.32, 95% CI = -0.56 to -0.08. No significant differences between augmentation with medication versus placebo were found in ratings of functional impairment and dropouts due to adverse events. Conclusions: Augmentation does not appear to be beneficial in treatment-resistant anxiety disorders. These results may be limited by small study samples, and a small number of overall studies in the analysis. (C) 2016 Wiley Periodicals, Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Psychiatry

Mental health during the first wave of COVID-19 in Canada, the USA, Brazil and Italy

Jasmine Turna, Beth Patterson, Carolina Goldman Bergmann, Nina Lamberti, Maryam Rahat, Heather Dwyer, Ana Paula Francisco, Matteo Vismara, Bernardo Dell'Osso, Beth Sideris, Michael Van Ameringen

Summary: The study found that despite differences in mental health among healthcare practitioners in different countries, the overall impact of the pandemic on mental health appeared to be similar. Canadian healthcare practitioners reported the highest rates of anxiety and depression, while non-healthcare practitioners in other countries reported higher symptom severity than healthcare practitioners.

INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE (2022)

Article Psychiatry

Obsessive-compulsive disorder during the COVID-19 pandemic

M. Van Ameringen, B. Patterson, J. Turna, G. Lethbridge, C. Goldman Bergmann, N. Lamberti, M. Rahat, B. Sideris, A. P. Francisco, N. Fineberg, S. Pallanti, G. Grassi, M. Vismara, U. Albert, R. Gedanke Shavitt, E. Hollander, J. Feusner, C. Rodriguez, P. Morgado, B. Dell'Osso

JOURNAL OF PSYCHIATRIC RESEARCH (2022)

Review Psychiatry

Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: A Systematic Review and Recommendations of Cannabis use in Bipolar Disorder and Major Depressive Disorder

Smadar V. Tourjman, Gabriella Buck, Didier Jutras-Aswad, Atul Khullar, Shane McInerney, Gayatri Saraf, Jairo V. Pinto, Stephane Potvin, Marie-Josee Poulin, Benicio N. Frey, Sidney H. Kennedy, Raymond W. Lam, Glenda MacQueen, Roumen Milev, Sagar V. Parikh, Arun Ravindran, Roger S. McIntyre, Ayal Schaffer, Valerie H. Taylor, Michael van Ameringen, Lakshmi N. Yatham, Serge Beaulieu

Summary: This task force report examines the association between cannabis use and bipolar disorder, major depressive disorder, and comorbid cannabis use disorder. The results indicate that cannabis use is associated with worsened course and functioning of both mood disorders, particularly in bipolar disorder. However, the treatment of comorbid cannabis use disorder and major depressive disorder did not show significant results.

CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE (2023)

Review Psychiatry

Advances in problematic usage of the internet research - A narrative review by experts from the European network for problematic usage of the internet

Naomi A. Fineberg, Jose M. Menchon, Natalie Hall, Bernardo Dell'Osso, Matthias Brand, Marc N. Potenza, Samuel R. Chamberlain, Giovanna Cirnigliaro, Christine Lochner, Joel Billieux, Zsolt Demetrovics, Hans Jurgen Rumpf, Astrid Muller, Jesus Castro-Calvo, Eric Hollander, Julius Burkauskas, Edna Grunblatt, Susanne Walitza, Ornella Corazza, Daniel L. King, Dan J. Stein, Jon E. Grant, Stefano Pallanti, Henrietta Bowden-Jones, Michael Van Ameringen, Konstantinos Ioannidis, Lior Carmi, Anna E. Goudriaan, Giovanni Martinotti, Celia M. D. Sales, Julia Jones, Biljiana Gjoneska, Orsolya Kiraly, Beatrice Benatti, Matteo Vismara, Luca Pellegrini, Dario Conti, Ilaria Cataldo, Gianluigi M. Riva, Murat Yucel, Maeva Flayelle, Thomas Hall, Morgan Griffiths, Joseph Zohar

Summary: This article reviews the scientific progress and knowledge gaps in the field of problematic usage of the internet (PUI) and highlights the importance of research goals, including better understanding of the course and evolution of PUI-related problems, reliable methods for early identification of at-risk individuals, efficacious preventative and therapeutic interventions, and ethical health and social policy changes that safeguard digital rights.

COMPREHENSIVE PSYCHIATRY (2022)

Article Psychiatry

The role of gender in a large international OCD sample: A Report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) Network

Beatrice Benatti, Nicolaja Girone, Laura Celebre, Matteo Vismara, Eric Hollander, Naomi A. Fineberg, Dan J. Stein, Humberto Nicolini, Nuria Lanzagorta, Donatella Marazziti, Stefano Pallanti, Michael van Ameringen, Christine Lochner, Oguz Karamustafalioglu, Luchezar Hranov, Martin Figee, Lynne M. Drummond, Jon E. Grant, Damiaan Denys, Leonardo F. Fontenelle, Jose M. Menchon, Joseph Zohar, Carolyn Rodriguez, Bernardo Dell'Osso

Summary: This study found significant differences between genders in OCD, with females having a higher proportion of adult onset, older age at illness onset, lower education level, higher marriage rate, and higher rate of living with a partner compared to males. However, there were no significant gender differences in the severity of OCD symptoms or comorbid depressive symptoms. The researchers suggest that gender may influence the heterogeneity of OCD and may require different treatment strategies.

COMPREHENSIVE PSYCHIATRY (2022)

Article Psychiatry

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - Version 3. Part II: OCD and PTSD

Borwin Bandelow, Christer Allgulander, David S. Baldwin, Daniel Lucas da Conceicao Costa, Damiaan Denys, Nesrin Dilbaz, Katharina Domschke, Eric Hollander, Siegfried Kasper, Hans-Juergen Moeller, Elias Eriksson, Naomi A. Fineberg, Josef Haettenschwiler, Hisanobu Kaiya, Tatiana Karavaeva, Martin A. Katzman, Yong-Ku Kim, Takeshi Inoue, Leslie Lim, Vasilios Masdrakis, Jose M. Menchon, Euripedes C. Miguel, Antonio E. Nardi, Stefano Pallanti, Giampaolo Perna, Dan Rujescu, Vladan Starcevic, Dan J. Stein, Shih-Jen Tsai, Michael Van Ameringen, Anna Vasileva, Zhen Wang, Joseph Zohar

Summary: According to the guideline by the World Federation of Societies of Biological Psychiatry, OCD and PTSD can be effectively treated with medications and CBT. SSRIs and CBT are first-line treatments for OCD, while SSRIs and venlafaxine are first-line treatments for PTSD.

WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2023)

Article Psychiatry

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - Version 3. Part I: Anxiety disorders

Borwin Bandelow, Christer Allgulander, David S. Baldwin, Daniel Lucas da Conceicao Costa, Damiaan Denys, Nesrin Dilbaz, Katharina Domschke, Elias Eriksson, Naomi A. Fineberg, Josef Hattenschwiler, Eric Hollander, Hisanobu Kaiya, Tatiana Karavaeva, Siegfried Kasper, Martin Katzman, Yong-Ku Kim, Takeshi Inoue, Leslie Lim, Vasilios Masdrakis, Jose M. Menchon, Euripedes C. Miguel, Hans-Jurgen Moller, Antonio E. Nardi, Stefano Pallanti, Giampaolo Perna, Dan Rujescu, Vladan Starcevic, Dan J. Stein, Shih-Jen Tsai, Michael Van Ameringen, Anna Vasileva, Zhen Wang, Joseph Zohar

Summary: This study presents the third version of the guideline for the pharmacological treatment of anxiety, obsessive-compulsive, and posttraumatic stress disorders. It provides recommendations based on efficacy and acceptability of available treatments, evaluated through rigorous methods. The study highlights the importance of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) as first-line medications, and cognitive behavioral therapy (CBT) as the first-line psychotherapy for anxiety disorders.

WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2023)

Review Psychiatry

Treatments for child and adolescent attention deficit hyperactivity disorder in low and middle-income countries: A narrative review

Amy Pipe, Nisha Ravindran, Angela Paric, Beth Patterson, Michael Van Ameringen, Arun V. Ravindran

Summary: ADHD affects 2-7% of children globally, but treatment outcomes in low-and middle-income countries are rarely reported. Pharmacological treatments, especially methylphenidate, are more available than psychological interventions in these regions. More research is needed to improve mental health services and access to treatment for ADHD in LMICs.

ASIAN JOURNAL OF PSYCHIATRY (2022)

Review Psychiatry

The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder

Joshua D. Rosenblat, M. Ishrat Husain, Yena Lee, Roger S. McIntyre, Rodrigo B. Mansur, David Castle, Hilary Offman, Sagar Parikh, Benicio N. Frey, Ayal Schaffer, Kyle T. Greenwaym, Nicolas Garel, Serge Beaulieu, Sidney H. Kennedy, Raymond W. Lam, Roumen Milev, Arun Ravindran, Valerie Tourjman, Michael Van Ameringen, Lakshmi N. Yatham, Valerie Taylor

Summary: There is currently only low-level evidence to support the efficacy and safety of psychedelics for major depressive disorder.

CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE (2023)

Article Psychiatry

Treatment-resistant OCD: Pharmacotherapies in adults

Peter J. van Roessel, Giacomo Grassi, Elias N. Aboujaoude, Jose M. Menchon, Michael Van Ameringen, Carolyn Rodriguez

Summary: Serotonin reuptake inhibitor (SRI) medications are the first-line pharmacotherapeutic treatment for Obsessive-Compulsive Disorder (OCD), but a substantial proportion of patients do not respond well to these medications. This review discusses the clinical features associated with poor response to SRIs and presents alternative therapies for treatment-resistant OCD. Pharmacotherapies targeting various neurotransmitter systems and anti-inflammatory pathways have shown preliminary evidence of efficacy.

COMPREHENSIVE PSYCHIATRY (2023)

Review Psychiatry

Cannabis use in Attention-Deficit/Hyperactivity Disorder (ADHD): A scoping review

Ana Paula Francisco, Grace Lethbridge, Beth Patterson, Carolina Goldman Bergmann, Michael Van Ameringen

Summary: Treatment options for adult ADHD include stimulants, non-stimulant medications, and cognitive-behavioral therapy. Cannabis has been reported by patients to improve ADHD symptoms, but there is limited scientific literature on its effects. This study reviewed existing research on the effects of cannabis on ADHD symptoms and found mixed results.

JOURNAL OF PSYCHIATRIC RESEARCH (2023)

Review Substance Abuse

Cannabidiol as a candidate pharmacotherapy for sleep disturbance in alcohol use disorder

Marie N. S. Gendy, Benicio N. Frey, Michael Van Ameringen, Nirushi Kuhathasan, James MacKillop

Summary: Considering the limited availability of candidate medications for sleep disturbances in individuals with alcohol use disorder (AUD), this review critically examines the potential of cannabidiol (CBD) as a treatment for AUD-induced sleep disturbance. CBD's modulation of the endocannabinoid system and its favorable safety profile have generated substantial interest for its therapeutic use. Preclinical and clinical studies suggest promise for CBD in restoring normal sleep-wake cycle and enhancing sleep quality in AUD patients. Well-designed randomized controlled trials are needed to further investigate CBD's potential in managing this challenging feature of AUD.

ALCOHOL AND ALCOHOLISM (2023)

Article Psychiatry

Periodicity and severity of changes in depression and anxiety during the COVID-19 pandemic: Ten-wave longitudinal findings from an observational cohort study of community adults

Molly L. Scarfe, Kyla Belisario, Jessica Gillard, Jane De Jesus, Benicio N. Frey, Michael Van Ameringen, Margaret C. McKinnon, Mahmood R. Gohari, Jason W. Busse, James MacKillop

Summary: This study examined the mental health changes during the COVID-19 pandemic through 10 waves of data collection. Depression and anxiety showed significant changes, initially increasing and then decreasing over time. The severity of depression and anxiety before the pandemic moderated these changes, with lower severity participants experiencing increases and higher severity participants showing no significant change or decreases. Approximately 10% to 11% exhibited minimal important differences (MID) increases in depression and anxiety, while approximately 4% to 6% exhibited MID decreases.

PSYCHIATRY RESEARCH (2023)

Meeting Abstract Neurosciences

Correlates and Patterns of Cannabis Use in an ADHD Sample

Michael Van Ameringen, Barbara T. M. Q. dos Santos, Beth Patterson, Maryam Rahat, Juliette Mojgani, Grace Lethbridge, Fernando Sumiya, Carolina Goldman Bergmann

NEUROPSYCHOPHARMACOLOGY (2022)

Article Pharmacology & Pharmacy

Attitudes and Beliefs Toward Cannabis Before Recreational Legalization: A Cross-Sectional Study of Community Adults in Ontario

Jasmine Turna, Iris Balodis, Michael Van Ameringen, Jason W. Busse, James MacKillop

Summary: This study provides a comprehensive description of attitudes towards cannabis among Canadian adults before legalization. The results show that most individuals hold positive attitudes towards medical cannabis and have a realistic perception of the risks associated with cannabis use. However, a notable proportion of individuals underestimate the risk of cannabis use disorder and overestimate the benefits for mental health.

CANNABIS AND CANNABINOID RESEARCH (2022)

暂无数据